Advertisement
It has now been discovered that TB does not lie "dormant" but is actuallywaging a constant war with the host, constantly re-infecting the lungs.Provided that the host is healthy, it has the upper hand and usually keepsthe TB in check - LTBI. TB is particularly tricky to eliminate as it can beeither replicating, when it can be killed by the antibiotics, ornon-replicating when antibiotics are useless. The long, nine month course ofantibiotics is needed to ensure that all traces of the non-replicating formare eliminated from the lungs. Further details can be found athttp://www.archivelfarma.com/hipotesi_an.html
Advertisement
Archivel's novel, two pronged approach combines a one month course ofantibiotic to eliminate the bacteria in the replicating stage and twoinjections of the company's RUTI vaccine that stimulates the body's ownimmune system to fight the TB bacteria. This combination approach reduces thetreatment time from nine months to one, is easier to manage, less expensive,more effective and more likely to be done completely. The company estimatesthat cost comparison between the current and new treatment, when allowing forall the logistical costs means that the new treatment costs around half thatof the old treatment.
Further information at http://www.archivelfarma.com/noticies_an.html
Full details can be found in the accompanying press release AF004002entitled "Archivel's RUTI, a novel therapeutic vaccine to LatentTuberculosis, starts phase II clinical trials in South Africa" and pressrelease AF004001 entitled "Major breakthrough in fight to eliminateTuberculosis".
Further information on Archivel at http://www.archivelfarma.com
Archivel Farma S.L., 61 c/ Fogars de Tordera, Poligon IndustrialBonavista, 08916 BADALONA, Spain. Tel +34-93-497-2456, +34-637-057432,[email protected]
Press information and illustrations
Nigel Robson, Vortex PR, Tel +44(0)1481-233080, [email protected]
RUTI is a registered trademark of Archivel Farma S.L.
SOURCE Archivel Farma
